Last reviewed · How we verify
Locoid Lipocream
At a glance
| Generic name | Locoid Lipocream |
|---|---|
| Also known as | Topical skin barrier repair therapies (BRT) |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD (PHASE4)
- Evaluation of the Vasoconstriction Properties of MC2-01 Cream (PHASE1)
- Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis (PHASE4)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
- Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream (NA)
- Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Locoid Lipocream CI brief — competitive landscape report
- Locoid Lipocream updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI